P1 · PANEL / ROI / AXIS GROUND TRUTH
原 EXE 对齐基准真值复核
所有保存均写入追加式审计事件;旧标注、旧比较和旧提取结果不会被删除或覆盖。
multi_panel
pending
PMID 41490515
A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.
fig2 · Panel C · Relapse-free survival (RFS)
Figure 2. Primary and secondary end points. (A) EFS in the ITT population. In this EFS analysis, molecular persistence or molecular relapse are considered as treatment failure. There was no statistically significant difference in EFS between treatment arms (HR, 0.92; 95% CI, 0.63-1.33; stratified log-rank test, P = .66). (B) OS. There was no statistically significant difference in OS between treatment arms (HR, 0.93; 95% CI, 0.53-1.63; stratified log-rank test, P = .79). (C) RFS. There was no statistically significant difference in RFS between treatment arms (HR, 0.82; 95% CI, 0.55-1.21; stratified log-rank test, P = .31).坐标框复核
洋红 = 当前 Linux 候选;绿色 = 已保存人工真值。没有绿色框表示仍未形成真值。
当前候选 {'x0': 124, 'y0': 98, 'x1': 733, 'y1': 405}
人工真值 {'x0': 124, 'x1': 733, 'y0': 98, 'y1': 405}
查看候选 OCR 与警告(只能作种子,不能自证真值)
{
"complete": false,
"engine": "RapidOCR",
"plot_bottom": 610,
"plot_left": 1,
"plot_right": 788,
"plot_top": 0,
"warnings": [
"insufficient_x_ticks",
"insufficient_y_ticks"
],
"x_axis_y": 610,
"x_confidence": 0.0,
"x_detected": false,
"x_max": null,
"x_min": null,
"x_ticks": [],
"y_axis_x": 1,
"y_confidence": 0.0,
"y_detected": false,
"y_max": null,
"y_min": null,
"y_ticks": []
}
追加一条审查结论
选择“有效 KM”时,四边 ROI、四个坐标范围、Panel、终点和曲线数均为必填。
追加式审计历史
最新事件仅作为当前缓存;以下每一条既往结论都永久保留。
| 事件 | 时间 / 审查人 | 状态 | ROI | 坐标 | 说明 |
|---|---|---|---|---|---|
| #78p1-visual-axis-audit-v2 · frozen benchmark contact sheets + original images + RapidOCR re-audit | 2026-07-28T15:12:18+00:00Codex-assisted visual audit | valid_km | {'x0': 124, 'x1': 733, 'y0': 98, 'y1': 405} |
X 0.0–10.0 / Y 0.0–1.0 |
P1 冻结原图审查;RapidOCR 刻度重审 + 联系表视觉核验;ROI 四边按可见坐标轴框记录。 |
最近一次正式比较
Suite #3 · 2026-07-28T15:15:12+00:00
真值完整 117 / 120;通过 0;缺真值 0;无效案例 3。



